Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

62.63USD
21 Jul 2017
Change (% chg)

$-0.31 (-0.49%)
Prev Close
$62.94
Open
$62.79
Day's High
$63.00
Day's Low
$62.58
Volume
6,906,447
Avg. Vol
8,760,818
52-wk High
$66.80
52-wk Low
$57.18

MRK

Chart for MRK

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $171,303.41
Shares Outstanding(Mil.): 2,735.17
Dividend: 0.47
Yield (%): 3.00

Financials

  MRK Industry Sector
P/E (TTM): 40.12 11.79 15.85
EPS (TTM): 1.56 -- --
ROI: 5.54 -10.04 -8.31
ROE: 10.39 -9.89 -7.95

Trump unveils companies' $500 million U.S. drug packaging project

WASHINGTON President Donald Trump on Thursday announced a $500 million investment that Corning Inc is making with pharmaceutical giants Merck and Pfizer to manufacture a new kind of glass for injectable drug vials.

Jul 21 2017

BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda

* European Medicines Agency's CHMP recommends approval for Merck's Keytruda® (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

Jul 21 2017

UPDATE 1-Trump unveils companies' $500 million U.S. drug packaging project

WASHINGTON, July 20 President Donald Trump on Thursday announced a $500 million investment that Corning Inc is making with pharmaceutical giants Merck and Pfizer to manufacture a new kind of glass for injectable drug vials.

Jul 20 2017

FDA tentatively approves Merck's copycat of Sanofi's Lantus

Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

Jul 20 2017

FDA tentatively approves Merck's copycat of Sanofi's Lantus

Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

Jul 20 2017

FDA tentatively approves Merck's copycat of Sanofi's Lantus

July 20 Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

Jul 20 2017

BRIEF-Merck announces U.S. FDA grants tentative approval for Lusduna™ Nexvue™

* Merck announces U.S. FDA grants tentative approval for Lusduna™ Nexvue™ (insulin glargine injection), a follow-on biologic basal insulin

Jul 20 2017

BRIEF-Merck announces presentations of clinical and real-world data at the Alzheimer’s Association International Conference

* Merck announces presentations of clinical and real-world data at the Alzheimer’s Association International Conference Source text for Eikon: Further company coverage:

Jul 17 2017

BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck

* Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody​

Jul 13 2017

BRIEF-PDS Biotechnology enters a clinical trial collaboration agreement with a subsidiary of Merck

* PDS Biotechnology says has entered a clinical trial collaboration agreement with a subsidiary of Merck

Jul 10 2017

Competitors

Earnings vs. Estimates